1. Introduction {#sec1}
===============

In the context of the COVID-19 pandemic, several existing approved drugs and experimental antiviral agents have been repurposed as potential antiviral candidates for the treatment of COVID-19 infection. While preliminary choices were essentially based on *in vitro* potency, clinical translation into effective therapies may be challenging due to unfavorable *in vivo* pharmacokinetic (PK) properties (i.e. plasma protein binding, tissue distribution, drug interactions) at the doses chosen for this new indication of COVID-19 infection. The particular conditions of COVID-19 infection (cytokine storm, multi-visceral failure and life-threatening prognosis), patient co-morbidities (i.e. obesity, diabetes, cardiovascular complications) and the requirement for a short and rapidly effective treatment further complicate the choice of the ideal candidate.

Remdesivir, chloroquine derivatives (essentially hydroxychloroquine (HCQ) due to a better safety profile than chloroquine) and the anti-HIV agent lopinavir (LPV) were among the first to be tested due to an *in vitro* antiviral activity demonstrated against SARS-CoV-2 or other similar respiratory viruses (i.e. SARS-CoV, MERS-CoV). Although remdesivir is not yet commercially available, other agents are already easily accessible to clinical investigators as they are part of the therapeutic armamentarium of other diseases (i.e. systemic lupus erythematosus (SLE) for HCQ and human immunodeficiency virus (HIV) treatment for LPV) probably explaining the large number of ongoing clinical trials worldwide. Favipiravir, ribavirin, tocilizumab, ivermectin, nafamostat and other agents have also been proposed for treatment of COVID-19 infection either as antivirals or immunomodulatory agents ([@bib44]).

In the area of infectious diseases and antiviral drugs, pharmacological properties are of particular importance for treatment choices, evaluation and optimization. Indeed, suboptimal antiviral response may be a consequence of inadequate exposure and/or poor PK-PD properties of the studied drug. From the HIV pandemic, we have learned that maintaining sufficient plasma drug exposure is critical to stop virus replication and avoid emergence of resistances ([@bib19]). This has led to the implementation of strategies to optimize dosing regimen such as the PK "boosting", used in the lopinavir/ritonavir (LPV/r) association. In this area, increasing knowledge on the PK and pharmacokinetic-pharmacodynamic (PK-PD) relationships of antiretrovirals has also demonstrated its usefulness in treatment optimization through the use of therapeutic drug monitoring ([@bib6]). In the context of COVID-19 infection, optimizing drug exposure at the site of infection, *i.e.* in the respiratory tract, is probably the key to successful treatment.

Accurate collection of PK and PD data is therefore of primary importance, especially for these repurposed drugs. We believe that extrapolation of PK data from other clinical situations may require specific caution due to different physiopathological conditions. In the context of the current global emergency, the number of clinical trials is rapidly increasing in order to quickly generate the data required for efficient patient healthcare. However, we have found that some of the pharmacology data published so far are somewhat disappointing, due to a lack of information permitting adequate comprehension of the dose-exposure and dose-effect relationships ([@bib17]; [@bib39]) and the poor representativeness of data used for simulations of effective dosing regimens ([@bib15]; [@bib39]; [@bib53]).

For these reasons and on behalf of the Clinical Pharmacology Committee of the French agency for AIDS and viral hepatitis research (ANRS) and the Therapeutic Drug Monitoring and Treatment Personalization working group of the French Society of Pharmacology and Therapeutics (SFPT), we believe that there is an urgent need for clarifications and improvements in order to generate high-quality PK and PK-PD data for the drugs to be used for COVID-19 treatment.

2. Limitations of available PK and PK-PD data {#sec2}
=============================================

Few studies have already described PK and PK-PD in potential treatments for COVID-19 infection and only a small fraction of ongoing clinical trials have planned to do so. We were only able to find 18 out of the 1546 registered in [clinicaltrials.gov](http://clinicaltrials.gov){#intref0010} ([Table 1](#tbl1){ref-type="table"} ) ([www.clinicaltrials.gov](http://www.clinicaltrials.gov){#intref0015}, accessed on: May 18, 2020). The list presented here is representative of the current situation though not necessarily exhaustive. The situation is particularly striking for the commonly used repurposed drugs HCQ and LPV for which only 2 trials, one in children and another in adults, were designed to measure concentration data ([Table 1](#tbl1){ref-type="table"}). PK analyses are preferentially planned for new drugs (i.e. monoclonal antibodies) not yet approved in another indication, such as to take advantage of COVID-19 infection to acquire PK data in humans. [@bib39] and [@bib17] have reported HCQ blood or serum concentrations from COVID-19 patients. However, in these two papers, very little methodological, demographic, clinical, paraclinical and even dosing information that could help to better understand the dose-exposure relationship in COVID-19 patients is available. Perinel et al. have succinctly described a small population of intensive care unit (ICU) patients receiving 200 mg of HCQ three times daily without loading dose in which HCQ whole blood concentrations were measured ([@bib39]). A similar dosing regimen was used by [@bib17] but serum concentrations were determined instead. Apparently, for their study, they have reported the sum of HCQ and its metabolite concentrations. Whether the approximation used to quantify HCQ metabolite is valid ([@bib17]) and whether this metabolite is active on SARS-CoV-2 require further evaluation. Anyway, simply summing-up the concentrations of the active moiety and its metabolite cannot effectively contribute to comprehension of PK and PK-PD relationships since they may present different PK and/or PD properties and consequently misrepresent the adequate drug exposure ([@bib48]). These preliminary observations also raise the question of the selection of the adequate biological matrix (blood vs plasma or serum) for PK assessment of HCQ.Table 1Pharmacological issues relative to COVID-19 infection in clinical trials: 18 studies found for: **Pharmacokinetic \| COVID-19**.Table 1Clinical trial IdentifierOfficial TitlePrimary outcomeExperimental drugPharmacologicalNCT04345614A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients with Severe COVID-19 PneumoniaSafety, efficacy, and the PK profile of CM4620-IE in patients with severe COVID-19 pneumonia.CM4620-Injectable EmulsionM4620-IE serum concentrationNCT04357613A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients. \[Time Frame: 30 days\]Imatinib 800 mg/d during 14daysTo evaluate plasma levels of imatinib \[Time Frame: 14 days\]\
Imatinib trough levelNCT04346628A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19Time until cessation of oral shedding of SARS-CoV-2 virus \[ Time Frame: Up to 28 days \]Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2--10).Cmax of favipiravir \[Time Frame: Days 1 and 10 (samples taken 30 min prior to and 1 h following favipiravir administration)\]NCT04358549Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19Time to viral clearance \[Time Frame: Day 29\]; To determine the effect of favipiravir + SOC v. SOC on viral clearance of COVID-19 as measured by nasopharyngeal and oropharyngeal samplingDay 1: favipiravir 1800 mg BID plus Standard of Care (SOC) Days 2--14: 1000 mg BID plus SOC. For subjects with Child-Pugh A liver impairment: Days 2--14: 800 mg BID plus SOCPlasma PK of favipiravirNCT03891420A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19Number of subjects with 1- treatment emergent adverse events and serious adverse events\
2- change in laboratory parametersGalidesivir IV infusionExposure of galidesivir as measured by plasma concentrationsNCT03648372An Open Label, Dose-Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019COVID-19 proof of concept: Once the Safety Lead-in is complete and a TAK-981 dose and regimen is selected by the Safety Monitoring Committee (SMC), the randomized COVID-19 proof of concept will begin with participants randomized to Arm A: COVID-19 standard of care (SOC), or Arm B COVID-19 SOC + TAK-981.TAK-981 Intravenous infusionTAK-981 COVID-19 safety lead-in: TAK-981, intravenously, administered as 60 min-infusion, once on Days 1 and 4. The starting dose of TAK-981 will be 60 mg (mg).NCT04371640A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With COVID-19Change in SARS-COV-2 viral burden from baseline to day 7 of treatment \[Time Frame: Baseline, and days 1, 2, 3, 4, 5, 6, & 7 post-dose for all patients\]\
SARS-COV-2 viral burden will be quantified for both arms using a qRT-PCRSirolimus + standard medical care Day 1: 10 mg Days 2--7: 5 mg\
Intervention: Drug: Sirolimus 1 MG/MLPK of sirolimusNCT04363736A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4 mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 PneumoniaConcentration of C-Reactive Protein (CRP) \[Time Frame: Day 7\]Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg vs 4 mg/kg in addition to standard-of-care treatment.Concentration of C-Reactive Protein (CRP) as surrogate marker of TCZ PKNCT04320615A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 PneumoniaClinical Status Assessed Using a 7-Category Ordinal Scale \[ Time Frame: Day 28 \]Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.Serum Concentration of TCZ \[Time Frame: Up to 60 days\]NCT04158648A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors17 primary outcomes4 loading doses of emicizumab 3 mg/kg will be administered subcutaneously once a week (QW) for 4 weeks followed by participant\'s preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).Plasma Trough Concentration (Ctrough) of Emicizumab Over Time \[Time Frame: Pre-dose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, and 49, and every 12 weeks thereafter until study completion/discontinuation (up to approximately 30 months)\]NCT04278404Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied DrugsUsual PK parametersAminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir,\
Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine- Immediate Release, Fosfomycin\
Furosemide, Gabapentin\
Guanfacine, Hydrocortisone\
Labetalol, Meropenem, Metformin\
Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate/Sevelamer, Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid\
Voriconazole, Zolpidem\
Dextroamphetamine/Amphetamine - Extended Release, Azithromycin\
Chloroquine, Hydroxychloroquine, Lopinavir/Ritonavir, Ribavirin, TocilizumabThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:\
The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.NCT04392219A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy VolunteersSafety and Tolerability of Single Ascending Dose (SAD) of EIDD-2801 (Part 1) and Multiple Ascending Dose (MAD) of EIDD-2801 (Part 3): Adverse Events \[ Time Frame: From screening through study completion, up to 15 days \]\
Number and severity of treatment emergent adverse eventsPart 1: Subjects will be randomized to receive a single oral dose of EIDD-2801 or Placebo.\
Part 3: Subjects will be randomized to receive twice daily dosing either EIDD-2801 or Placebo.Pharmacokinetics (PK) of EIDD-2801 when given as Single Doses (Part 2): Maximum observed concentration Cmax \[ Time Frame: Day 1 through Day 18 \]\
Multiple pharmacokinetic variables of EIDD-2801 will be assessed and may include, but are not limited to: Maximum observed concentration CmaxNCT04346199A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Subject alive and free of respiratory failure \[ Time Frame: Day 14 \]Acalabrutinib- administered orallyPlasma PK parameters of acalabrutinib and its active metabolite ACP- 5862 \[ Time Frame: 28 days after last dose \]NCT04380688A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19Occurrence of Adverse Events and Serious Adverse Events \[Time Frame: 28 days after last dose\]\
Subject alive and free of respiratory failure \[Time Frame: Day 14\]Acalabrutinib- administered orallyPlasma PK parameters of acalabrutinib and its active metabolite ACP- 5862 \[Time Frame: 28 days after last dose\]NCT04350736A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19Safety and Tolerability of MAD of TD-0903: Adverse Events \[ Time Frame: Day 1 to Day 14 \]\
Number and severity of treatment emergent adverse eventsTD-0903\
Study drug to be administered by inhalationPlasma PK parameters of SAD and MAD TD-0903NCT04369469A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress SyndromeSurvival (based on all-cause mortality) at Day 29 \[ Time Frame: Baseline, Day 29 \]Weight-based doses of ravulizumab will be administered intravenously on Days 1, 5, 10, and 15.\
Other Names:\
Ultomiris\
ALXN1210PK parameters of ravulizumabNCT04379271A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator\'s Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19Proportion of patients without any need for INV until end-of-study (EoS) \[ Time Frame: Throughout the Study (Day 0 to Day 28) \]\
Clinicaltwice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC)Morning trough plasma levels of IMU-838 on Days 0, 1, 2, 3, 6, 14, and 28 \[ Time Frame: on Days 0, 1, 2, 3, 6, 14, and 28 \]NCT04315948Multi-center, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized AdultsPercentage of subjects reporting each severity rating on a 7-point ordinal scale \[ Time Frame: Day 15 \]aNot hospitalized, no limitations on activitiesbNot hospitalized, limitation on activities;cHospitalized, not requiring supplemental oxygen;dHospitalized, requiring supplemental oxygen;eHospitalized, on non-invasive ventilation or high flow oxygen devices;fHospitalized, on invasive mechanical ventilation or ECMO;gDeath.Remdesivir will be administered as a 200 mg intravenous loading dose on Day 1, followed by a 100 mg once-daily intravenous maintenance dose for the duration of the hospitalization up to a 10 days total course.\
Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-mL suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.\
Interferon ß1a will be administered subcutaneously at the dose of 44 μg for a total of 3 doses in 6 days (day 1, day 3, day 6).\
Hydroxychloroquine will be administered orally as a loading dose of 400 mg twice daily for one day followed by 400 mg once daily for 9 days. The loading dose of hydroxychloroquine through a nasogastric tube will be increased to 600 mg twice a day for one day, followed by a maintenance dose of 400 mg once a day for 9 daysPlasma concentration of lopinavir \[ Time Frame: Days 1, 3, 5, 8 and 11 \]\
On Day 1, plasma concentration 4 h after the first administration (peak), and before the second administration (trough at H12)\
On Days 3, 5, 8 and 11, trough plasma concentration (before dose administration) while hospitalized\
Plasma concentration of hydroxychloroquine \[ Time Frame: Days 1, 3, 5, 8 and 11 \]\
On Day 1, plasma concentration 4 h after the first administration (peak), and before the second administration (trough at H12)\
On Days 3, 5, 8 and 11, trough plasma concentration (before dose administration) while hospitalized

Some of these papers ([@bib15]; [@bib39]; [@bib53]) have built dosing recommendations for HCQ based on PK models previously developed in other diseases (SEL, malaria) and clinical situations (steady-state, non-ICU patients), which raises questions about the relevance of such recommendations. [@bib39] have graphically compared measured HCQ blood concentrations in COVID-19 patients to PK simulations obtained with a HCQ population PK model initially developed for rheumatoid arthritis (RA) patients ([@bib10]). Results clearly demonstrate the inadequacy of a population PK model developed for stable chronic RA patients to describe actual PK data obtained in ICU patients. This point has also been confirmed by Martin-Blondel et al. ([@bib29]) in their attempt to describe HCQ plasma concentrations obtained in COVID-19 patients using a PK model initially developed for SLE patients. As a consequence, we believe that due to probably large PK differences affecting either clearance or volume of distribution as demonstrated with other anti-infective drugs, this type of PK model should not be used to simulate any dosing regimens for ICU patients ([@bib42]). Whether these models could be applied to less severe COVID patients, at the early stage of the disease, requires confirmation. It is likely that models developed in healthy volunteers may be appropriate in the prophylaxis setting. The population PK-PD model developed by [@bib15] to describe viral decline and QTc prolongation after HCQ administration in COVID-19 patients, may theoretically enable achievement of more robust simulation results. For the PK part of the model, they used a population PK model initially developed using plasma concentrations obtained from healthy Korean volunteers and Korean patients receiving HCQ for treatment of vivax malaria ([@bib27]). To demonstrate the adequacy of this model for COVID-19 patients, they used published serum concentrations obtained in non-severe and non-ICU COVID-19 patients drawn from the study by [@bib17] described above. Although some differences between serum and plasma concentrations cannot be ruled out ([@bib4]), they showed that HCQ concentrations from COVID-19 patients fell within the lower range of expected population profiles, thereby suggesting that this model could be appropriate to describe the PK of HCQ, at least in non-ICU COVID-19 patients. However, one should note that the concentration data set used for this model validation expressed HCQ concentration as the sum of the active moiety and its metabolite ([@bib17]), consequently leading to systematic overestimation of actual exposure to HCQ. Other limitations of this paper apply to the PD parts of the model since viral kinetic data are from SARS-CoV-1 and the concentration/QTc prolongation data were obtained from a study with chloroquine. Limitations also apply to the study by [@bib53], who developed a PB-PK model to simulate different dosing regimens for HCQ in COVID-19 patients. Indeed, HCQ concentrations in lung were simulated by incorporating in their model blood-to-lung concentration data obtained by analyzing tissue homogenates after dosing in rats ([@bib30]). This approach may provide unreliable diffusion data in lungs ([@bib35]; [@bib37]) and consequently unreliable simulations at the site of infection. Similar limitations of this lung model have been discussed by [@bib14] and by [@bib54].

Similarly, a steady-state population PK model initially developed from HIV patients receiving standard dose LPV/r has been used to simulate LPV total and free concentrations for comparison with various virological endpoints, i.e. actual IC50 values for HIV-1, MERS-CoV and SARS-CoV ([@bib47]). From a PK perspective, this model is probably unable to describe actual LPV concentrations currently measured in COVID-19 patients, which are as recently reported ([@bib20]) much higher than those observed in HIV patients. Furthermore, this recent paper showed that despite very high plasma LPV concentrations observed in patients, the free fraction, representing the active part of the drug, was not affected ([@bib20]).

Concerning favipiravir, a recent comment proposes to evaluate higher doses for SARS-CoV-2 than in Ebola disease, based on both *in vitro* EC50 and PK simulations data associated with a close monitoring of adverse events and plasma concentrations ([@bib13]). However, favipiravir is a prodrug, and determination of tissue and intracellular exposure of the activate metabolite favipiravir-ribofuranosyl-5-triphosphate would be required in order to better characterize PK-PD relationship ([@bib12]).

No such attempts have been made with remdesivir, yet. Furthermore, data on the diffusion of these drugs into the pulmonary tract are lacking.

3. Recommendations for improvements {#sec3}
===================================

We propose here to identify some of the major requirements that need to be addressed in designing PK and PK-PD studies in this era of COVID.

4. Pre-analytical and analytical requirements {#sec4}
=============================================

Pre-analytical and analytical steps should be strictly controlled to guarantee the necessary accuracy of measured concentrations. For LPV, well-standardized sampling and assay procedures have been defined for the monitoring of HIV patients and we believe that these procedures may adequately apply to COVID-19 patients. By contrast, this is more confusing with HCQ since it could be analyzed either in whole blood ([@bib10]) or in plasma ([@bib34]; [@bib49]). In the area of anti-infective drugs, plasma may appear as the preferred matrix since free plasma concentration is in equilibrium with tissue concentrations and the putative site of action. Moreover, some PK-PD relationships have been commonly developed for antivirals using plasma concentration as a surrogate for the concentrations at the site of action ([@bib41]). However, as regards plasma, it appears that the pre-analytical step is of particular importance for chloroquine derivatives since early observations have shown that chloroquine could be released from blood cells, leading to overestimation of plasma concentrations ([@bib4]). Preliminary pre-analytical data suggest a similar pattern with HCQ when blood is not rapidly centrifuged and plasma separated. Moreover, HCQ blood-to-plasma ratio presents wide between-subject variability according to disease context and equilibrium distribution ([@bib34]; [@bib50]) suggesting that extrapolation from one to another is not reliable. Pre-analytical treatment of plasma for remdesivir assay requires an acidic stabilization step (Gilead, personal communication). Regarding the analytical step, robust specific and sensitive assays targeting individual analytes (active moiety and metabolites) have already been developed and validated for clinical pharmacokinetics. In the event of matrix modification (blood vs. plasma), a partial validation could be considered (European Medicines Agency. Guideline on bioanalytical method validation, 2011). In addition, inter-laboratory comparisons should be organized, especially in case of multicenter PK studies.

5. Collection of covariates affecting dose-exposure relationships {#sec5}
=================================================================

In order to comprehensively understand and describe dose-exposure relationships, collection of accurate dosing information, demographic, clinical and para-clinical data is mandatory.

Regarding dosing information, galenic forms and routes of administration are important data. It is common practice in the setting of an ICU, where the patient is unable to swallow solid oral dosage forms, to administer drugs through enteral feeding tubes. In this situation, the administration of crushed tablets in the feeding tube may have an impact on bioavailability, which may alter the dosing-exposure relationship of the studied drug. This has been demonstrated in the HIV setting where crushing tablets of LPV have led to a 45% decrease in AUC ([@bib5]). Surprisingly, crushing tablet does not appear to have a significant impact on the oral bioavailability of HCQ (Sanofi, personal communication).

The dosing regimen may include a loading dose that is particularly important in view of more rapidly achieving effective concentrations. This point is critical for HCQ due to its very long half-life ([@bib26]; [@bib49]). A loading dose has also been suggested for LPV ([@bib47]) and is required for remdesivir (European Medicines Agency. Summary on remdesivir compassionate use. April 2020).

Knowledge of co-administered drugs is likewise of primary importance, particularly in the context of ICU, where many medications are involved or when complications such as secondary infections are present, requiring co-administration of antibacterials and antifungals ([@bib44]). Co-medications are also frequent in patients particularly at risk for severe COVID-19, i.e. chronic disease patients such as obese and/or diabetic patients. Indeed, drug-drug interactions may occur at each step of the ADME process, leading to altered pharmacokinetics and, possibly, in increased variability of drug exposure. Divalent cations, such as calcium or magnesium, may interfere with the absorption of chloroquine ([@bib31]), thereby reducing its bioavailability. Similarly, LPV and HCQ, which undergo CYP mediated metabolism (Liverpool HIV group. Liverpool COVID-19 Interactions. <https://www.covid19-druginteractions.org/>, 2020), could be victims of drug-drug interactions affecting both bioavailability and clearance. Although remdesivir is also a substrate for CYP isoenzymes *in vitro*, its metabolism is likely to be predominantly mediated by hydrolase activity (Liverpool HIV group. Liverpool COVID-19 Interactions. <https://www.covid19-druginteractions.org/>, 2020), but this does not stave off inter- nor intra-patient variability.

Anthropometric characteristics, which are currently involved in PK variability, should be collected as well. Body weight has been described as a significant covariate of HCQ clearance in Japanese patients suffering from systemic lupus erythematosus ([@bib34]). Whether this relationship is valid in COVID-19 patients requires confirmation.

The use of specific organ support techniques ([@bib55]) such as renal replacement therapy (hemodialysis, hemofiltration, hemodiafiltration) or ventilation support (high-flow oxygen therapy, noninvasive ventilation, invasive mechanical ventilation and extracorporeal membrane oxygenation, ECMO) should be reported in order to assess their impact on drug exposure. A significant impact of hemodialysis on the pharmacokinetics of HCQ ([@bib49]) and LPV ([@bib21]) is unlikely but requires confirmation since steady-state conditions are not achieved in COVID-19 patients. An impact of ECMO on chloroquine pharmacokinetics has been described ([@bib2]) but no convincing data exist yet for LPV ([@bib18]). However, a significant impact of ECMO should be considered since several studies have shown altered PK profiles in this situation ([@bib22]). These data need to be confirmed in COVID-19 patients, especially considering differences in steady-state attainment.

Importantly, severe COVID-19 is associated with a systemic hyper-inflammation state, the so-called cytokine storm, which is associated with highly elevated C-reactive protein (CRP) levels, hyperferritinaemia and increased cytokine levels (IL-1β, IL-2, IL-6, IL-17, IL-8, TNF and CCL2) ([@bib32]). The impact of inflammation on the pharmacokinetics of drugs has already been highlighted. For example, several studies have reported a positive association between CRP levels and voriconazole or tacrolimus concentrations ([@bib8]; [@bib16]). The extent of increase in voriconazole concentration could be explained by downregulation of CYP isoenzymes by inflammatory stimuli leading to reduced metabolism ([@bib33]). Impact may also occur through altered expression of membrane transporters ([@bib46]). Preliminary data suggest a major decrease of LPV clearance in COVID-19 patients, highlighting the putative role of inflammation in these PK alterations.

6. Development of population PK and PK-PD models {#sec6}
================================================

Population approaches, which rely on PK-PD modeling, appear particularly appealing in this situation because these models can handle sparse data originating from different sources (ICU, non-ICU, dialysis patients) and different dosing regimens. Further, covariates as described above can be included in these population models to identify PK and pharmacodynamic (PD) variability factors. Finally, population-PK and PK-PD models have proven useful in the area of infectious diseases, providing a valuable tool to explore and predict efficient dosing regimens ([@bib25]). However, we believe that the development of population PK models specifically dedicated to acute COVID-19 patients is urgently needed due to major physiopathological differences with chronically ill HIV, RA and SEL patients. For that purpose, a collaborative multicenter study within clinical centers involved in clinical trials with these drugs may enable collection of the amount of data necessary to develop such a PK model. Such a collaborative project is ongoing within our groups.

Current dosing regimens proposed for these repurposed drugs are empirical since they have not been specifically developed for COVID-19 but rather for HIV, malaria and chronic inflammatory diseases. In order to develop more efficient dosing regimens, we also need reliable PD data to relate the concentration at the site of infection to viral sensitivity through the development of PK-PD models. Viral sensitivity could be determined through the measurement of EC50 or EC90 either in presence or in absence of human serum. Addition of human serum enables representation of the impact of drug protein binding on drug potency. EC50 is available for HCQ ([@bib28]; [@bib53]), LPV ([@bib11]), favipiravir ([@bib13]), remdesivir ([@bib11]) and other drugs such as ivermectin ([Table 2](#tbl2){ref-type="table"} ). But, as observed in [Table 2](#tbl2){ref-type="table"}, translation into effective therapies may be challenging due to unfavorable *in vivo* PK properties. For example, ivermectin, total (bound and unbound) plasma concentrations are \>45 times lower than the *in vitro* EC50. Since ivermectin is highly bound to plasma protein and its accumulation into human lung unknown ([@bib45]), the likelihood for ivermectin to reach IC50 at the site of action after the approved dose is low. The large variability reported in EC50 values between studies, mainly explained by differences in experimental conditions or mechanism of action, may also contribute to the difficulty of determining the accurate target concentration *in vivo*. For example, with HCQ, we observed high variability between EC50 values (i.e. for HCQ: from 0.72 μM ≈ 0.24 μg/mL to more than 15 μM ≈ 5 μg/mL) depending on multiplicity of infections (MOIs), incubation duration, presence/absence of human serum, etc ..., which may be of PK relevance for a drug presenting such a narrow therapeutic index. As reported in [Fig. 1](#fig1){ref-type="fig"} , HCQ median plasma concentrations could be 1.5 to 15 times lower than the *in vitro* EC50 depending on the scheme of administration and EC50 values. Moreover, the choice of experimental cells (Vero E6 cells or pulmonary epithelial cells) may be crucial for such respiratory viruses, although no consensus has yet arisen, and extrapolations from other viruses appear speculative ([@bib47]). Finally, regarding the lack of specificity/sensitivity of the current virological marker (i.e viral load in the upper respiratory tract) to assess antiviral activity, the combination of multiple PD parameters could be of interest. The relationships between viral load and clinically relevant endpoints is mostly unknown. Indeed, many clinical endpoints could be considered: mortality, recovery, hospital discharge, respiratory failure, need for oxygenation or mechanical ventilation, time-to-intubation, hospitalization, duration of hospital-stay, ICU admission, time-to-improvement, severity scores (SOFA), etc. Selecting the best clinically relevant endpoint may depend upon several factors such as its clinical relevance, its measurement\'s reliability, disease severity and statistical considerations.Table 2Available EC50 against SARS-CoV-2 and corresponding total plasma concentrations obtained in human.Table 2Repurposed drug*In vitro* antiviral activity against SARS-CoV-2Plasma total concentrations in human (SARS-CoV-2 infected patients)Plasma total concentrations in human (others populations)LopinavirEC~50~ = 26.63 μM (16.75 μg/mL) ([@bib11])\
EC~50~ = 15.27 μM (9.60 μg/mL) ([@bib24])400/100 mg BID: C~trough~ \[11.4--30.8 μg/mL\]\
400/100 mg QD: C~trough~ \[8.7--18.3 μg/mL\]([@bib20])RemdesivirEC~50~ = 0.77 μM (0.46 μg/mL) ([@bib52])\
EC~50~ = 23.15 μM (13.95 μg/mL) ([@bib11])\
EC~50~ = 8.24 μM (4.97 μg/mL) ([@bib24])\
EC~50~ = 165 ± 0.79 μM (99.43 μg/mL) ([@bib51])**Healthy subjects**\
100 mg QD for 5--10 days:\
Mean (SD) GS-443902 C~24~ in PBMCs = 10.2 (5.5) μM (Day 5) (European Medicines Agency. Summary on remdesivir compassionate use. April 2020)HydroxychloroquineEC~50~ = 0.72 μM (0.24 μg/mL) ([@bib53])\
EC~50~ = 4.51 μM (1.47 μg/mL) ([@bib28])\
EC~50~ = 4.17 μM (1.35 μg/mL) ([@bib51])200 mg TID MD without LD: C~trough~ = 0.09 ± 0.01 (H8 on day 2) to 0.19 ± 0.06 (H8 on day 6) μg/mL\
400mgx2 LD on day 1 followed by 400 × 1 MD: C~trough~ = 0.09 ± 0.12 (H12 on day 2) to 0.13 ± 0.14 (H12 on day 6) μg/mL (Martin-Blondel et al., n.d.)FavipiravirEC~50~ = 9.4 μg/mL\
EC~50~ = 40--80 μg/mL ([@bib13])\
EC~50~ \> 100 μM (\>15.71 μg/mL) ([@bib11])\
EC~50~ \> 500 μM (\>78.55 μg/mL) ([@bib24])**Ebola patients**\
6000 mg on day 0 followed by 1200 mg BID for 9 days: Median (range) C~trough~ = 46.1 (2.3--106.9) μg/mL on day 2 and 25.9 (0--173.2) μg/mL on day 4 ([@bib36])IvermectinEC~50~ = 2 μM (1750 ng/mL) ([@bib9])**Onchocerciacis patients**\
Single dose of 150 μg/kg PO: C~max~ = 38.2 ± 5.8 ng/mL ([@bib38])[^2]Fig. 1Observed hydroxychloroquine plasma concentrations (median) after 3--5 days of treatment in patients treated for SARS-CoV-2 infection depending on the scheme of administration: 400 mg QD after a loading dose of 400mgx2 on day 1 and 200 mg TID without any loading dose (C. Solas, internal data from the Pharmacokinetics and Toxicology Laboratory). Solid line represent i*n vitro* EC50 described against SARS-CoV-2 at T48h post incubation.Fig. 1

In order to assess drug penetration to the site of action, determination of drug concentration in bronchoalveolar lavage could be proposed as a surrogate for lung concentrations. Urea or albumin should be used as a marker of dilution to determine the volume of epithelial lining fluid recovered and samples should be preferably collected at multiple time points throughout the dosing interval ([@bib43]). To our knowledge, corresponding data for COVID-19 treatment candidates are scarce. A case study in a single HIV patient ([@bib1]) reported significant LPV concentration in BAL at steady-state. ELF and total plasma concentrations were 14.4 and 8.1 μg/mL, respectively. The corresponding ratio of ELF over total plasma concentrations was 1.8, suggesting an accumulation of LPV in ELF requiring confirmation in COVID-19 patients. Data of the same order of magnitude but with less accumulation were also reported by [@bib7].

7. Conclusion {#sec7}
=============

Available PK and PK-PD studies suffer from severe limitations leading to unreliable conclusions, especially in term of dosing optimization. At this time, there is still no high-quality evidence to support the use of these repurposed drugs for the treatment of COVID-19. Therefore, implementation of well-designed PK and PD studies specifically targeted to COVID-19 patients is urgently needed in order to increase our comprehension of the dose-exposure-effect relationships of the repurposed drugs. Without these data, efficient evaluation and development of effective dosing regimens will remain difficult. Other scientific societies ([@bib3]) and organizations ([@bib23]; [@bib40]) have also recently issued call to action for the appropriate application of clinical pharmacology principles in the search for COVID-19 treatments. Further, to accelerate the production of up-to-date PK and PD data and the development of meaningful PK and PK-PD models, we also call for multi-institutional collaborative work and involvement of clinical pharmacologists in multidisciplinary research consortia.
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[^2]: \*Remdesivir is a prodrug rapidly converted to a circulating monophosphate nucleoside analog (GS-441524) which inside cells undergoes rapid conversion to the pharmacologically active analog of adenosine triphosphate (GS-443902) that inhibits viral RNA polymerases. LD = loading dose, MD = maintenance dose.
